

REVISION ANNOUNCEMENT OF FINANCIAL FORECASTS FOR FY2008

Tokyo, Japan – 26 December 2008: Sosei Group Corporation (“Sosei”; TSE Mothers Index: 4565), a biopharmaceutical company, announced today the revisions to its financial forecasts for the Fiscal Year ending March 2009, updating from the forecasts announced on 14 May 2008.

1. Revised Financial Forecasts for the Fiscal Year 2008 (1 April 2008 – 31 March 2009)
(JY: Million)

	Sales	Ordinary Profit/(Loss)	Net Income/(Loss)
Original Forecast (A)	190	(3,180)	(3,180)
Revised Forecast (B)	190	(3,450)	(3,450)
Increase (Decrease) (B-A)	—	(270)	(270)
Increase (Decrease) %	—	—	—

2. Reasons for Revision

As a result of the company decision to re-acquire commercialization rights from Mundipharma for a mutually agreed sum of £2m, Ordinary Loss and Net Loss have been revised accordingly.

An additional payment of 20% (up to maximum of £1.5m) of net receipts, that Sosei is obliged to pay in case it enters into a new partnership agreement, is not reflected in the above figures.

For further details please see today’s news release “*Sosei Announces Buyback of the Commercialization Rights to AD 923 from Mundipharma*”.

- Ends -

Enquiries:

Sosei Group Corporation

Ichiban-cho FS Bldg., 8 Ichiban-cho, Chiyoda-ku, Tokyo 102-0082 Japan

Hiroki MAEKAWA, Representative Executive Officer,

E-mail: hmaekawa@sosei.com

Tel: +81-3-5210-3399

Fax: +81-3-5210-3291

1F London BioScience Innovation Centre

2 Royal College Street, London NW1 0NH

Non OSAKABE, PA to CEO

E-mail: nosakabe@sosei.com

Tel: +44-20-7691-2081

Fax: +44-20-7209-2484